For the twelve months ended Jul 31, 2026, MiniMed Group Inc. reported $3.22B of revenue and -$309.00M of net income.
MMED revenue was $843.00M in fiscal Q1 2027 (ended Jul 31, 2026), up 16.6% from a year earlier and up 0.7% from the prior quarter. For the full fiscal 2026 it was $3.10B, up 14.3% from fiscal 2025.
MMED net income was $0 in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$19.00M a year earlier. For the full fiscal 2026 it was -$333.00M, compared with -$213.00M in fiscal 2025.
MMED diluted EPS was $0.00 in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$0.08 a year earlier. For the full fiscal 2026 it was -$1.30, compared with -$0.84 in fiscal 2025.
MMED free cash flow was -$90.00M in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$194.00M a year earlier. For the full fiscal 2026 it was -$420.00M, compared with -$53.00M in fiscal 2025.
| Line item | Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 |
|---|---|---|---|
| Revenue | $3.10B | $2.71B | $2.47B |
| Cost of revenue | $1.42B | $1.19B | $1.03B |
| Gross profit | $1.68B | $1.53B | $1.44B |
| Research and development | $448.00M | $436.00M | $437.00M |
| Selling, general and admin | $1.18B | $1.08B | $1.06B |
| Operating income | -$190.00M | -$146.00M | -$69.00M |
| Pre-tax income | -$189.00M | -$147.00M | -$70.00M |
| Income tax | $128.00M | $52.00M | $38.00M |
| Net income | -$333.00M | -$213.00M | -$112.00M |
| EPS, basic | -$1.30 | -$0.84 | -$0.44 |
| EPS, diluted | -$1.30 | -$0.84 | -$0.44 |
| Diluted shares | 256.6M | 252.8M | 252.8M |
| Line item | Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 |
|---|---|---|---|
| Cash and equivalents | $298.00M | $11.00M | $54.00M |
| Receivables | $200.00M | $570.00M | - |
| Inventory | $341.00M | $311.00M | - |
| Current assets | $1.35B | $939.00M | - |
| Goodwill | $2.26B | $2.25B | - |
| Total assets | $4.63B | $4.20B | - |
| Current liabilities | $702.00M | $710.00M | - |
| Total liabilities | $1.02B | $871.00M | - |
| Shareholders' equity | $3.61B | $3.33B | $3.45B |
| Line item | Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 |
|---|---|---|---|
| Operating cash flow | -$197.00M | $140.00M | $41.00M |
| Capital expenditures | $223.00M | $193.00M | $148.00M |
| Free cash flow | -$420.00M | -$53.00M | -$107.00M |
| Investing cash flow | -$233.00M | -$193.00M | -$157.00M |
| Financing cash flow | $716.00M | $10.00M | $112.00M |
| Stock-based compensation | $46.00M | $41.00M | $38.00M |
| Depreciation and amortization | $156.00M | $143.00M | $129.00M |
| Line item | Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 |
|---|---|---|---|
| Revenue growth, YoY | 14.3% | 10.0% | - |
| Gross margin | 54.2% | 56.3% | 58.2% |
| Operating margin | -6.1% | -5.4% | -2.8% |
| Net margin | -10.7% | -7.8% | -4.5% |
| Free cash flow margin | -13.5% | -2.0% | -4.3% |
| Return on equity | -9.2% | -6.4% | -3.2% |
| Return on assets | -7.2% | -5.1% | - |
| Current ratio | 1.92 | 1.32 | - |
| Line item | Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $843.00M | $837.00M | $790.00M | $752.00M | $723.00M | $724.00M | $687.00M | - | - |
| Cost of revenue | $378.00M | $357.00M | $428.00M | $323.00M | $314.00M | $318.00M | $292.00M | - | - |
| Gross profit | $465.00M | $480.00M | $362.00M | $429.00M | $409.00M | $405.00M | $395.00M | - | - |
| Research and development | $115.00M | $99.00M | $114.00M | $110.00M | $125.00M | $107.00M | $112.00M | - | - |
| Selling, general and admin | $312.00M | $299.00M | $309.00M | $292.00M | $283.00M | $276.00M | $268.00M | - | - |
| Operating income | $5.00M | -$93.00M | -$100.00M | $16.00M | -$13.00M | -$148.00M | $21.00M | - | - |
| Pre-tax income | $4.00M | -$92.00M | -$99.00M | $15.00M | -$13.00M | -$148.00M | $21.00M | - | - |
| Income tax | $4.00M | $93.00M | $12.00M | $20.00M | $3.00M | $21.00M | $28.00M | - | - |
| Net income | $0 | -$185.00M | -$119.00M | -$5.00M | -$19.00M | -$172.00M | -$10.00M | -$5.00M | -$19.00M |
| EPS, basic | $0.00 | - | -$0.47 | - | -$0.08 | - | -$0.04 | - | - |
| EPS, diluted | $0.00 | - | -$0.47 | - | -$0.08 | - | -$0.04 | - | - |
| Diluted shares | 281.0M | - | 252.8M | - | 252.8M | - | 252.8M | - | - |
| Line item | Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $207.00M | $298.00M | $10.00M | - | $9.00M | $11.00M | $10.00M | - | - |
| Receivables | $180.00M | $200.00M | $653.00M | - | - | $570.00M | - | - | - |
| Inventory | $356.00M | $341.00M | $408.00M | - | - | $311.00M | - | - | - |
| Current assets | $1.42B | $1.35B | $1.11B | - | - | $939.00M | - | - | - |
| Goodwill | $2.25B | $2.26B | $2.26B | - | - | $2.25B | - | - | - |
| Total assets | $4.72B | $4.63B | $4.34B | - | - | $4.20B | - | - | - |
| Current liabilities | $782.00M | $702.00M | $696.00M | - | - | $710.00M | - | - | - |
| Total liabilities | $1.10B | $1.02B | $881.00M | - | - | $871.00M | - | - | - |
| Shareholders' equity | $3.62B | $3.61B | $3.46B | $3.56B | $3.54B | $3.33B | $3.48B | $3.46B | $3.48B |
| Line item | Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.00M | -$170.00M | - | - | -$141.00M | $83.00M | - | - | - |
| Capital expenditures | $41.00M | $56.00M | - | - | $53.00M | $57.00M | - | - | - |
| Free cash flow | -$90.00M | -$226.00M | - | - | -$194.00M | $26.00M | - | - | - |
| Investing cash flow | -$41.00M | -$56.00M | - | - | -$63.00M | -$57.00M | - | - | - |
| Financing cash flow | $0 | $512.00M | - | - | $202.00M | -$25.00M | - | - | - |
| Stock-based compensation | $10.00M | $8.00M | - | - | $9.00M | $9.00M | - | - | - |
| Depreciation and amortization | $41.00M | $39.00M | - | - | $39.00M | $38.00M | - | - | - |
| Line item | Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 16.6% | 15.6% | 15.0% | - | - | - | - | - | - |
| Gross margin | 55.2% | 57.3% | 45.8% | 57.0% | 56.6% | 55.9% | 57.5% | - | - |
| Operating margin | 0.6% | -11.1% | -12.7% | 2.1% | -1.8% | -20.4% | 3.1% | - | - |
| Net margin | 0.0% | -22.1% | -15.1% | -0.7% | -2.6% | -23.8% | -1.5% | - | - |
| Free cash flow margin | -10.7% | -27.0% | - | - | -26.8% | 3.6% | - | - | - |
| Current ratio | 1.81 | 1.92 | 1.59 | - | - | 1.32 | - | - | - |
Source: XBRL data MiniMed Group Inc. files with the SEC, latest filing dated Sep 8, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MMED | $3.22B | - | -$309.00M | -9.6% | $4.70B |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.05B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $95.67B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $61.96B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $57.71B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $52.13B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.10B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $29.62B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $27.85B |